Shares of American Express Company AXP have lost more than 6 percent since the start of 2018. and one Wall Street analyst said the multiple risks faced by the company are discounted in the stock.
The Analyst
Nomura Instinet's Bill Carcache upgraded American Express Co. from Neutral to Buy with an unchanged $108 price target.
The Thesis
Nomura Instinet's Buy rating is predicated on, at the very least, the charge card issuer meeting expectations, Carache said in a Monday note. Multiple negative catalysts are priced into the stock at current levels, he said.
The analyst's estimates assume AmEx will suspend its stock buyback for 2018 as it regroups after charges related to the tax legislation signed by President Donald Trump.
Carache named the following as risks for AmEx:
- Slowing earnings per share growth.
- "Growth math" headwinds.
- An increased reliance on spread lending.
AmEx's positives include the following, Carache said:
- A healthy macroeconomic backdrop.
- Expectations for a stable growth revenue profile ahead.
- Limited co-brand renewal risk in light of recent signings.
AmEx, along with other credit card stocks, is "oversold" — and if the company merely meets the Street's EPS estimates, the stock could move higher by 18 percent and trade at a 13.6x multiple on 2019E EPS, Carache said.
Price Action
Shares of American Express were up nearly 4 percent early Monday afternoon.
Related Links:
Buy American? American Express Recovery Is Not Without Its Risks
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.